Levetiracetam-induced parkinsonism in a huntington disease patient

Clinical Neuropharmacology

Volumn 29, Issue 6, 2006, Pages 303-304

  Gatto, Emilia Mabel ^a   Roca, Claudia Uribe ^a,b   Etcheverry, José Luis ^a   Fadel, Daniel ^c  

^a INEBA Neurosciences Institute of Buenos Aires   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM;

ADULT; ANAMNESIS; CASE REPORT; DRUG DOSE REDUCTION; HUMAN; HUNTINGTON CHOREA; LABORATORY TEST; LETTER; MALE; MINI MENTAL STATE EXAMINATION; PARKINSONISM; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ADULT; HUMANS; HUNTINGTON DISEASE; MALE; NOOTROPIC AGENTS; PARKINSONIAN DISORDERS; PIRACETAM;

EID: 33750914888     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000240946.51994.DF     Document Type: Letter

References (6)

1. Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, et al. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol 2005;28:188-190.
2. Meco G, Fabrizio E, Epifanio A, et al. Levetiracetam in L-dopa-induced dyskinesia. Clin Neuropharmacol 2005;28:102-103.
3. Schauer R, Singer M, Saltuari L, et al. Suppression of cortical myoclonus by levetiracetam. Mov Disord 2002;17:411-415.
4. Sullivan KL, Hauser RA, Louis ED, et al. Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord 2005;7:469-471.
5. Recio MV, Hauser RA, Louis ED, et al. Chorea in a patient with cerebral palsy: treatment with levetiracetam. Mov Disord 2005;20:762-764.
6. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004;101:9861-9866.